Bill 19 changes the Pharmaceutical Services Act to remove the mandatory use of tamper‑resistant prescription pads for certain listed controlled drugs in specific situations. The amendments let pharmacists or dispensing physicians dispense listed controlled drugs when the prescription is received by telephone (if the federal Controlled Drugs and Substances Act or its regulations/exemptions allow it), when the prescription is transferred from another dispenser (again, subject to federal authorization), when the prescriber sends the prescription directly to the dispensing pharmacy, and when the pharmacist substitutes an equivalent therapeutic controlled drug.
These changes narrow the provincial paper‑pad rule while explicitly deferring to the federal Controlled Drugs and Substances Act and its exemptions. For pharmacists, prescribers, and pharmacies this alters verification and documentation practices and shifts some compliance judgments toward interpreting federal permissions and local procedures rather than an across‑the‑board pad requirement.
At a Glance
What It Does
The bill amends subsections of section 26 to permit dispensing certain controlled drugs without a tamper‑resistant pad in four circumstances: telephone prescriptions where federal law permits, transfers from another dispenser where federal law permits, prescriptions sent directly from prescriber to pharmacy, and pharmacist substitutions to therapeutically equivalent controlled drugs.
Who It Affects
Licensed pharmacists and dispensing physicians in Newfoundland and Labrador, community and hospital pharmacies, prescribers who send prescriptions directly, and regulators who enforce controlled‑drug rules. Patients in remote or continuity‑of‑care situations are indirectly affected by changed access and workflow.
Why It Matters
The bill aligns provincial dispensing requirements with federal CDSA permissions and reduces instances where paper pad formality blocks dispensing. That reduces operational friction for pharmacies but requires coordination with federal rules, and creates areas where professional judgment and recordkeeping carry more legal weight.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act still keeps a list of drugs for which a tamper‑resistant prescription pad is ordinarily required, but Bill 19 carves out four specific exceptions to that requirement. First, a pharmacist or dispensing physician may now fill a listed controlled drug when the prescription was received by telephone if the federal Controlled Drugs and Substances Act (CDSA), its regulations or a federal exemption allow telephone prescribing for that drug.
Second, the pad requirement does not apply when a prescription is transferred from another pharmacist or dispensing physician, again only when federal rules permit such a transfer. Third, the pad requirement is removed when the prescriber sends the prescription directly to the dispensing pharmacy.
Fourth, the pharmacist or dispensing physician may substitute an equivalent therapeutic controlled drug without the tamper‑resistant pad.
Practically, the changes mean provincial law no longer imposes an absolute paper‑pad rule in those four scenarios; instead the CDSA and its exemptions become the gatekeeper for telephone and transfer cases. Pharmacists and dispensing physicians who rely on these exceptions must therefore confirm that the specific controlled drug and the transmission method are authorized under the CDSA framework.
The bill does not create new federal permissions — it only permits dispensing without the pad when federal law already allows the transmission or substitution.Operationally, pharmacies will need to update policies and staff training to document the legal basis for dispensing under the exceptions: which federal provision or exemption permits telephone prescribing or transfers, evidence that the prescription was transmitted directly by the prescriber, and documentation of the therapeutic equivalence when substituting controlled drugs. The bill repeals subsection 26(6.2), removing whatever prior narrow rule that subsection contained and consolidating the exceptions into the new language.For prescribers, the amendment removes a provincial obstacle to direct transmission methods (electronic or otherwise), but it does not itself validate any particular electronic system; prescribers must still use transmission methods that meet federal and professional standards.
For regulators and enforcement bodies, the change shifts many compliance questions from a simple form‑based test (was a tamper‑resistant pad used?) to a facts‑based inquiry (was the method permitted by the CDSA, was the transfer legitimate, was the substitution clinically appropriate?).
The Five Things You Need to Know
The bill replaces subsection 26(5) and (5.1) to allow telephone prescriptions for listed controlled drugs only where the federal Controlled Drugs and Substances Act, its regulations, or a federal exemption authorizes telephone prescribing for that drug.
It replaces subsection 26(6.1) to permit dispensing without a tamper‑resistant pad when a prescription is transferred from another pharmacist or dispensing physician, but only if the transfer is permitted by the CDSA framework.
Dispensing without a tamper‑resistant pad is also allowed when the prescriber sends the prescription directly to the dispensing pharmacy, irrespective of a transfer or telephone rule.
The bill authorizes pharmacists or dispensing physicians to substitute a prescribed listed controlled drug with a therapeutically equivalent controlled drug without requiring a tamper‑resistant pad for the substitute.
The bill repeals subsection 26(6.2) of the Pharmaceutical Services Act, consolidating the exceptions into the new substituted provisions.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Telephone prescriptions: conditional exception tied to federal law
This provision removes the blanket provincial bar on dispensing listed controlled drugs when the prescription is received by telephone and replaces it with a conditional rule: pharmacists and dispensing physicians may fill a telephone prescription only where the federal CDSA, its regulations, or a federal exemption allows telephone prescribing for that particular drug. The practical effect is to defer to federal permissions — provincial law no longer adds an extra prohibition but also does not expand federal authorities.
Transfers, direct transmission, and substitutions: three specific pad exceptions
This new subsection lists three discrete circumstances in which a tamper‑resistant pad is not required: (a) transfers from another pharmacist or dispensing physician where the CDSA permits such transfers, (b) prescriptions sent directly from prescriber to dispensing pharmacy, and (c) pharmacist substitutions to therapeutically equivalent controlled drugs. Each clause has different operational triggers and evidence needs — for transfers and telephone cases the clause ties back to the CDSA; for direct prescriber transmission and substitution the provision removes the pad requirement without explicit federal gating but still leaves professional standards and other laws in play.
Removal of a prior provision — consolidation of exceptions
The bill repeals subsection 26(6.2) entirely. Repealing this subsection appears intended to streamline the Act by consolidating the limited exceptions into the new 26(6.1). The repeal may eliminate a narrower or alternative pathway that previously existed; practitioners should compare the old text to the new language to identify any loss of a previously available route.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Community pharmacists and dispensing physicians — reduced paperwork friction when filling prescriptions received by phone, via transfer, direct transmission, or when substituting therapeutically equivalent controlled drugs; fewer rejected fills for form‑based technicalities.
- Patients in remote or continuity‑of‑care situations — faster access to needed controlled medications when a prescriber calls in a prescription, transfers exist between pharmacies, prescribers send prescriptions directly, or pharmacists perform clinically appropriate substitutions.
- Prescribers who transmit prescriptions directly — clearer provincial authorization to send controlled‑drug prescriptions straight to the dispensing pharmacy without triggering a pad requirement.
- Pharmacies managing inter‑pharmacy transfers — smoother transfer workflows where federal rules permit, reducing interruptions to treatment and administrative burden.
Who Bears the Cost
- Pharmacies and pharmacists — they must update policies, train staff, and document legal authority for each exception (citation to CDSA regulation or exemption, transfer records, evidence of direct transmission, substitution justification).
- Regulatory and enforcement bodies (provincial pharmacy regulator and inspectors) — investigations will become more fact‑intensive, requiring review of federal permissions and clinical records rather than a simple pad‑vs‑no‑pad check.
- Prescribers and their offices — if sending prescriptions directly, they must adopt secure transmission practices and documentation routines acceptable to pharmacies and regulators.
- Public health and law enforcement stakeholders — slightly greater risk of diversion or fraudulent prescriptions in edge cases could require increased monitoring or enforcement activity.
- Small or rural pharmacies lacking robust verification systems — these businesses may face higher compliance costs to prove that a telephone prescription, transfer, or substitution met legal standards.
Key Issues
The Core Tension
The central tension is access versus control: the bill improves patient access and reduces technical barriers by removing the pad requirement in several real‑world scenarios, but it also replaces a clear, auditable form requirement with a context‑sensitive standard that depends on federal permissions, clinical judgment, and documentary proof — raising risks of diversion and uneven enforcement unless regulators and practitioners tighten procedures and recordkeeping.
The amendments shift the compliance focus from a binary paperwork requirement (was a tamper‑resistant pad used?) to a context‑dependent inquiry that layers provincial permissibility on top of federal permissions. That creates practical complexity: for telephone and transfer cases, pharmacists must identify and cite the relevant CDSA provision or federal exemption that permits the transmission method for the specific drug.
In many cases those federal permissions are drug‑specific, time‑limited, or contingent on recordkeeping, forcing pharmacies to maintain up‑to‑date legal awareness and stronger audit trails.
The provision allowing substitutions without a tamper‑resistant pad raises clinical and liability questions. Pharmacists must determine therapeutic equivalence under professional standards while recognizing that substituting within the controlled‑drug category can carry heightened risk if monitoring and patient counseling are inadequate.
The text does not specify required documentation or a standard of proof for equivalence, leaving those details to professional guidance or regulatory interpretation. Finally, the repeal of subsection 26(6.2) simplifies the Act on its face but may remove a prior, narrow protection or pathway; stakeholders should compare the prior and new texts to identify any lost safeguards.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.